ALCAM (activated leukocyte cell adhesion molecule, CD166) belongs to the immunoglobulin superfamily and is involved in axon guidance, hematopoiesis, immune response and tumor metastasis. During embryogenesis, mRNA encoding ALCAM was expressed in the cardiac crescent and the neural groove at embryonic day (E) 7.75 and predominately in the tubular heart at E8.5. A newly generated monoclonal antibody against the ALCAM molecule (ALC-48) exclusively stained cardiomyocytes at E8.25–10.5. However, ALCAM expression was lost by cardiomyocytes by E12.5 and its expression shifts to a variety of organs during later stages. ALCAM was found to be a prominent surface marker for cardiomyocytes in early embryonic hearts. The transient expression of ALCAM during early developmental stages marks specific developmental stages in cardiomyocyte differentiation.

Keywords:
ALCAM, Cardiogenesis, Cardiomyocytes, Cell adhesion molecules, Cellular therapy, Embryonic development, In vitro differentiation
1.
Bowen, M.A., D.D. Patel, X. Li, B. Modrell, A.R. Malacko, W.C. Wang, H. Marquardt, M. Neubauer, J.M. Pesando, U. Francke (1995) Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med 181: 2213–2220.
2.
Bruder, S.P., N.S. Ricalton, R.E. Boynton, T.J. Connolly, N. Jaiswal, J. Zaia, F.P. Barry (1998) Mesenchymal stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation. J Bone Miner Res 13: 655–663.
3.
Davis, C.A. (1993) Whole-mount immunohistochemistry. Methods Enzymol 225: 502–516.
4.
Fraboulet, S., T. Schmidt-Petri, D. Dhouailly, O. Pourquie (2000) Expression of DM-GRASP/BEN in the developing mouse spinal cord and various epithelia. Mech Dev 95: 221–224.
5.
Hassan, N.J., A.N. Barclay, M.H. Brown (2004) Frontline: optimal T cell activation requires the engagement of CD6 and CD166. Eur J Immunol 34: 930–940.
6.
Kanki, J.P., S. Chang, J.Y. Kuwada (1994) The molecular cloning and characterization of potential chick DM-GRASP homologs in zebrafish and mouse. J Neurobiol 25: 831–845.
7.
Kawamata, S., C. Du, K. Li, C. Lavau (2002) Overexpression of the Notch target genes Hes in vivo induces lymphoid and myeloid alterations. Oncogene 21: 3855–3863.
8.
Konno, A., J.S. Ahn, H. Kitamura, M.J. Hamilton, J.A. Gebe, A. Aruffo, W.C. Davis (2001) Tissue distribution of CD6 and CD6 ligand in cattle: expression of the CD6 ligand (CD166) in the autonomic nervous system of cattle and the human. J Leukoc Biol 69: 944–950.
9.
Kristiansen, G., C. Pilarsky, C. Wissmann, S. Kaiser, T. Bruemmendorf, S. Roepcke, E. Dahl, B. Hinzmann, T. Specht, J. Pervan, C. Stephan, S. Loening, M. Dietel, A. Rosenthal (2005) Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 205: 359–376.
10.
Lunter, P.C., J.W. van Kilsdonk, H. van Beek, I.M. Cornelissen, M. Bergers, P.H. Willems, G.N. van Muijen, G.W. Swart (2005) Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res 65: 8801–8808.
11.
Mann, C.J., Y. Hinits, S.M. Hughes (2006) Comparison of neurolin (ALCAM) and neurolin-like cell adhesion molecule (NLCAM) expression in zebrafish. Gene Expr Patterns 6: 952–963.
12.
Monzen, K., I. Shiojima, Y. Hiroi, S. Kudoh, T. Oka, E. Takimoto, D. Hayashi, T. Hosoda, A. Habara-Ohkubo, T. Nakaoka, T. Fujita, Y. Yazaki, I. Komuro (1999) Bone morphogenetic proteins induce cardiomyocyte differentiation through the mitogen-activated protein kinase kinase kinase TAK1 and cardiac transcription factors Csx/Nkx-2.5 and GATA-4. Mol Cell Biol 19: 7096–7105.
13.
Ohneda, O., K. Ohneda, F. Arai, J. Lee, T. Miyamoto, Y. Fukushima, D. Dowbenko, L.A. Lasky, T. Suda (2001) ALCAM (CD166): its role in hematopoietic and endothelial development. Blood 98: 2134–2142.
14.
Patel, D.D., S.F. Wee, L.P. Whichard, M.A. Bowen, J.M. Pesando, A. Aruffo, B.F. Haynes (1995) Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells. J Exp Med 181: 1563–1568.
15.
Pourquie, O., C. Corbel, J.P. Le Caer, J. Rossier, N.M. Le Douarin (1992) BEN, a surface glycoprotein of the immunoglobulin superfamily, is expressed in a variety of developing systems. Proc Natl Acad Sci USA 89: 5261–5265.
16.
Stephan, J.P., L. Bald, P.E. Roberts, J. Lee, Q. Gu, J.P. Mather (1999) Distribution and function of the adhesion molecule BEN during rat development. Dev Biol 212: 264–277.
17.
Sudo, T., S. Nishikawa, N. Ohno, N. Akiyama, M. Tamakoshi, H. Yoshida, S. Nishikawa (1993) Expression and function of the interleukin 7 receptor in murine lymphocytes. Proc Natl Acad Sci USA 90: 9125–9129.
18.
Swart, G.W. (2002) Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol 81: 313–321.
19.
Swart, G.W., P.C. Lunter, J.W. Kilsdonk, L.C. Kempen (2005) Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration? Cancer Metastasis Rev 24: 223–236.
20.
Takakura, N., H. Yoshida, Y. Ogura, H. Kataoka, S. Nishikawa, S. Nishikawa (1997) PDGFR alpha expression during mouse embryogenesis: immunolocalization analyzed by whole-mount immunohistostaining using the monoclonal anti-mouse PDGFR alpha antibody APA5. J Histochem Cytochem 45: 883–893.
21.
van Kempen, L.C., J.J. van den Oord, G.N. van Muijen, U.H. Weidle, H.P. Bloemers, G.W. Swart (2000) Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol 156: 769–774.
22.
Verma, A., N.K. Shukla, S.V. Deo, S.D. Gupta, R. Ralhan (2005) MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology 68: 462–470.
23.
Weichert, W., T. Knosel, J. Bellach, M. Dietel, G. Kristiansen (2004) ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 57: 1160–1164.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.